Cargando…
Plasma levels of BDNF and EGF are reduced in acute stroke patients
Stroke affects almost 14 million people worldwide each year. It is the second leading cause of death and a major cause of acquired disability. The degree of initial impairment in cognitive and motor functions greatly affects the recovery, but idiosyncratic factors also contribute. These are largely...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218156/ https://www.ncbi.nlm.nih.gov/pubmed/35756121 http://dx.doi.org/10.1016/j.heliyon.2022.e09661 |
_version_ | 1784731816969633792 |
---|---|
author | Øverberg, Linda Thøring Lugg, Elise Fritsch Gaarder, Mona Langhammer, Birgitta Thommessen, Bente Rønning, Ole Morten Morland, Cecilie |
author_facet | Øverberg, Linda Thøring Lugg, Elise Fritsch Gaarder, Mona Langhammer, Birgitta Thommessen, Bente Rønning, Ole Morten Morland, Cecilie |
author_sort | Øverberg, Linda Thøring |
collection | PubMed |
description | Stroke affects almost 14 million people worldwide each year. It is the second leading cause of death and a major cause of acquired disability. The degree of initial impairment in cognitive and motor functions greatly affects the recovery, but idiosyncratic factors also contribute. These are largely unidentified, which contributes to making accurate prediction of recovery challenging. Release of soluble regulators of neurotoxicity, neuroprotection and repair are presumably essential. Here we measured plasma levels of known regulators of neuroprotection and repair in patients with mild acute ischemic stroke and compared them to the plasma levels in healthy age and gender matched controls. We found that the levels of BDNF and EGF were substantially lower in stroke patients than in healthy controls, while the levels of bFGF and irisin did not differ between the groups. The lower levels of growth factors highlight that during the acute phase of stroke, there is a mismatch between the need for neuroprotection and repair, and the brain's ability to induce these processes. Large individual differences in growth factor levels were seen among the stroke patients, but whether these can be used as predictors of long-term prognosis remains to be investigated. |
format | Online Article Text |
id | pubmed-9218156 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-92181562022-06-24 Plasma levels of BDNF and EGF are reduced in acute stroke patients Øverberg, Linda Thøring Lugg, Elise Fritsch Gaarder, Mona Langhammer, Birgitta Thommessen, Bente Rønning, Ole Morten Morland, Cecilie Heliyon Research Article Stroke affects almost 14 million people worldwide each year. It is the second leading cause of death and a major cause of acquired disability. The degree of initial impairment in cognitive and motor functions greatly affects the recovery, but idiosyncratic factors also contribute. These are largely unidentified, which contributes to making accurate prediction of recovery challenging. Release of soluble regulators of neurotoxicity, neuroprotection and repair are presumably essential. Here we measured plasma levels of known regulators of neuroprotection and repair in patients with mild acute ischemic stroke and compared them to the plasma levels in healthy age and gender matched controls. We found that the levels of BDNF and EGF were substantially lower in stroke patients than in healthy controls, while the levels of bFGF and irisin did not differ between the groups. The lower levels of growth factors highlight that during the acute phase of stroke, there is a mismatch between the need for neuroprotection and repair, and the brain's ability to induce these processes. Large individual differences in growth factor levels were seen among the stroke patients, but whether these can be used as predictors of long-term prognosis remains to be investigated. Elsevier 2022-06-10 /pmc/articles/PMC9218156/ /pubmed/35756121 http://dx.doi.org/10.1016/j.heliyon.2022.e09661 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Research Article Øverberg, Linda Thøring Lugg, Elise Fritsch Gaarder, Mona Langhammer, Birgitta Thommessen, Bente Rønning, Ole Morten Morland, Cecilie Plasma levels of BDNF and EGF are reduced in acute stroke patients |
title | Plasma levels of BDNF and EGF are reduced in acute stroke patients |
title_full | Plasma levels of BDNF and EGF are reduced in acute stroke patients |
title_fullStr | Plasma levels of BDNF and EGF are reduced in acute stroke patients |
title_full_unstemmed | Plasma levels of BDNF and EGF are reduced in acute stroke patients |
title_short | Plasma levels of BDNF and EGF are reduced in acute stroke patients |
title_sort | plasma levels of bdnf and egf are reduced in acute stroke patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218156/ https://www.ncbi.nlm.nih.gov/pubmed/35756121 http://dx.doi.org/10.1016/j.heliyon.2022.e09661 |
work_keys_str_mv | AT øverberglindathøring plasmalevelsofbdnfandegfarereducedinacutestrokepatients AT luggelisefritsch plasmalevelsofbdnfandegfarereducedinacutestrokepatients AT gaardermona plasmalevelsofbdnfandegfarereducedinacutestrokepatients AT langhammerbirgitta plasmalevelsofbdnfandegfarereducedinacutestrokepatients AT thommessenbente plasmalevelsofbdnfandegfarereducedinacutestrokepatients AT rønningolemorten plasmalevelsofbdnfandegfarereducedinacutestrokepatients AT morlandcecilie plasmalevelsofbdnfandegfarereducedinacutestrokepatients |